Case 1:18-cv-01363-CFC Document 1-9 Filed 09/04/18 Page 1 of 23 PageID #: 410
`Case 1:18-cv-01363-CFC Document1-9
`Filed 09/04/18
`Page 1 of 23 PagelD #: 410
`
`
`
`EXHIBIT I
`EXHIBIT |
`
`
`
`

`

`Case 1:18-cv-01363-CFC Document 1-9 Filed 09/04/18 Page 2 of 23 PageID #: 411
`
`(12) U n i t ed States P a t e nt
`Basey et al.
`
`US006339142B1
`US 6,339,142 Bl
`(io) Patent No.:
`Jan. 15, 2002
`(45) Date of Patent:
`
`(54) PROTEIN PURIFICATION
`
`(75)
`
`Inventors: Carol D. Basey, Winters; Greg S.
`Blank, Menlo Park, both of CA (US)
`
`(73) Assignee: Genentech, Inc., South San Francisco,
`CA (US)
`
`( * ) Notice:
`
`Subject to any disclaimer, the term of this
`patent is extended or adjusted under 35
`U.S.C. 154(b) by 0 days.
`
`(21) Appl. No.: 09/679,397
`
`(22) Filed:
`
`Oct. 3, 2000
`
`Related U.S. Application Data
`
`(62) Division of application No. 09/304,465, filed on May 3,
`1999
`(60) Provisional application No. 60/084,459, filed on May 6,
`1998.
`Int. CI.7
`(51)
`(52) U.S. CI
`
`A61K 39/395; C07K 16/30
`530/387.3; 424/133.1;
`424/138.1; 424/155.1; 530/388.85
`424/133.1, 138.1,
`424/155.1; 530/387.3, 388.85
`
`(58) Field of Search
`
`(56)
`
`References Cited
`
`U.S. PATENT DOCUMENTS
`
`4,966,851 A * 10/1990 Durance et al
`5,110,913 A * 5/1992 Coan et al
`5,112,951 A * 5/1992 Beidler et al
`5,115,101 A * 5/1992 Bloom et al
`5,118,796 A * 6/1992 Prior et al
`5,256,769 A * 10/1993 Kato et al
`5,279,823 A * 1/1994 Frenz et al
`5,451,662 A * 9/1995 Navem et al
`5,525,338 A * 6/1996 Goldenberg
`5,821,337 A
`10/1998 Carter et al
`6,005,081 A * 12/1999 Burton et al
`
`530/416
`530/416
`530/416
`530/416
`530/416
`530/416
`424/94.61
`530/416
`424/178.1
`530/387.3
`530/416
`
`FOREIGN PATENT DOCUMENTS
`
`EP
`EP
`EP
`
`333574
`556083
`460426 Bl
`
`9/1989
`8/1993
`9/1997
`
`WO
`WO
`
`WO 89/05157
`WO 96/33208
`
`6/1989
`10/1996
`
`OTHER PUBLICATIONS
`
`Carter et al., "Humanization of an anti-piss™7*2 antibody
`for human cancer
`therapy" Proc. Natl. Acad.
`Sci.
`89:4285^1289 (May 1992).
`Gagnon, P., "Ion Exchange Chromatography" Purification
`Tools for Monoclonal Antibodies, Tucson: Validated Biosys-
`tems, Inc., Chapter 4, pp. 57-86 (1996).
`Graf et al., "Ion exchange resins for the purification of
`monoclonal antibodies from animal cell culture" Biosepa-
`ration 4(l):7-20 (Feb. 1994).
`Harris,R., "Chromatographic Techniques for the Character(cid:173)
`ization of Human MAbs" (Slides presented at the Waterside
`Monoclonal Conference held at the Omni Waterside Hotel in
`Harborside-Norfolk, Virginia on Apr. 22-25,1996) pp. 1-7.
`Mhatre et al., "Purification of antibody Fab fragments by
`cation-exchange chromatography and pH gradient elution"
`Journal of Chromatography A 707 (2) :225-231 (Jul. 2 1,
`1995).
`Neidhardt et al., "Rapid, two-step purification process for
`the preparation of pyrogen-free murine immunoglobulin G1
`monoclonal antibodies" Journal of Chromatography
`590
`(2) :255-261 (1992).
`Sofer et al. Handbook of Process Chromatography: A Guide
`to Optimization, Scale-up, and Validation, San Diego:Aca-
`demic Press pp. 65-80 (1997).
`Tishchenko et al., "Effect of salt concentration gradient on
`separation of different types of specific immunoglobulins by
`ion-exchange chromatography on DEAE cellulose" Journal
`of Chromatography B 706 (1) : 157-166 (Feb. 27, 1998).
`
`* cited by examiner
`
`Primary Examiner—David Saunders
`(74) Attorney, Agent, or Firm—Wendy M. Lee
`
`(57)
`
`ABSTRACT
`
`A method for purifying a polypeptide by ion exchange
`chromatography is described which involves changing the
`conductivity and/or pH of buffers in order to resolve a
`polypeptide of interest from one or more contaminants.
`
`3 Claims, 7 Drawing Sheets
`
`

`

`Case 1:18-cv-01363-CFC Document 1-9 Filed 09/04/18 Page 3 of 23 PageID #: 412
`
`U.S. Patent
`
`Jan. 15, 2002
`
`Sheet 1 of 7
`
`US 6,339,142 Bl
`
`STEP A
`BIND POLYPEPTIDE
`TO ION EXCHANGER
`LOADING BUFFER
`(e.g. 50 mM NaCI or
`5.0 pH)
`
`STEP A
`BIND POLYPEPTIDE
`TO ION EXCHANGER
`LOADING BUFFER
`(e.g. 50 mM NaCI or
`8.0 pH)
`
`STEPB
`ELUTE CONTAMINANT(S)
`INTERMEDIATE BUFFER
`(e.g. 70 mM NaCI or
`5.4 pH)
`
`STEPB
`ELUTE CONTAMINANT(S)
`INTERMEDIATE BUFFER
`(e.g. 70 mM NaCI or
`7.6 pH)
`
`STEPC
`EQUILIBRATE
`ION EXCHANGER
`WASH BUFFER
`(e.g. 50 mM NaCI or
`5.0 pH)
`
`STEPD
`ELUTE POLYPEPTIDE
`ELUTION BUFFER
`(e.g. 95 mM NaCI or
`6.0 pH)
`
`STEPE
`REGENERATE
`ION EXCHANGER
`REGENERATION
`BUFFER
`(e.g. 1.0 M NaCI)
`
`FIG.. 1
`
`STEPC
`EQUILIBRATE
`ION EXCHANGER
`WASH BUFFER
`(e.g. 50 mM NaCI or
`8.0 pH)
`
`STEPD
`ELUTE POLYPEPTIDE
`ELUTION BUFFER
`(e.g. 95 mM NaCI or
`7.0 pH)
`
`STEPE
`REGENERATE
`ION EXCHANGER
`REGENERATION
`BUFFER
`(e.g. 1.0 M NaCI)
`
`FIG.-2
`
`

`

`Case 1:18-cv-01363-CFC Document 1-9 Filed 09/04/18 Page 4 of 23 PageID #: 413
`
`U.S. Patent
`
`Jan. 15,2002
`
`Sheet 2 of 7
`
`US 6,339,142 Bl
`
`WASH
`BUFFER
`50 mM NaCI
`
`LOADING
`BUFFER
`50 mM NaCI
`
`INTERMEDIATE
`BUFFER
`70 mM NaCI
`
`ELUTION
`BUFFER
`95 mM NaCI
`
`*
`
`REGENERATION
`BUFFER
`1.0 M NaCI
`
`F/G._3
`
`

`

`Case 1:18-cv-01363-CFC Document 1-9 Filed 09/04/18 Page 5 of 23 PageID #: 414
`
`U.S. Patent
`
`Jan. 15,2002
`
`Sheet 3 of 7
`
`US 6,339,142 Bl
`
`i
`
`i
`
`i i
`
`i
`
`i
`
`i
`
`i i I
`
`i
`
`i
`
`i
`
`i
`
`I
`
`i
`
`i
`
`i
`
`i
`
`I
`
`i
`
`i
`
`i
`
`i
`
`I
`
`i
`
`i i
`
`i
`
`i
`
`i
`
`i
`
`i
`
`o
`H
`O
`<
`LL
`>
`X
`Q.
`<
`DC
`CD
`O
`
`O
`DC
`X o
`
`i
`CD
`
`R ^^ ^<<«^<^<^<m
`
`O
`O
`CL
`
`O
`O
`Q.
`UJ
`OC
`CL
`
`E^
`
`r^.
`
`E E E E E
`en en
`CT
`en O)
`E E E E E
`LD
`O
`LD
`o
`m
`CvJ C\J CO CO
`T-
`
`E JZ
`
`5
`
`LU
`
`<
`UJ
`^
`•
`
`E
`en
`E
`o
`p
`
`cn
`Q.
`LU
`h-
`cn
`X
`<
`
`S N N S S ^?
`
`E [V7X7
`
`X
`i &
`o
`
`DC
`
`O
`LL
`
`I
`
`I
`
`I
`
`I
`
`o
`CO
`
`I
`o
`r-
`
`I
`
`I
`
`I
`
`I
`
`j 1
`o
`CD
`
`I
`
`I
`
`I
`
`I
`
`I
`
`I
`O
`m
`
`i
`
`i
`
`i i
`
`i i
`O
`CO
`
`i i ]
`o
`CM
`
`O
`-sT
`
`i
`
`i
`
`i
`
`i
`
`i
`
`TT
`r
`
`i
`o
`
`Q
`_j
`LU
`>-
`
`

`

`Case 1:18-cv-01363-CFC Document 1-9 Filed 09/04/18 Page 6 of 23 PageID #: 415
`
`U.S. Patent
`
`Jan. 15,2002
`
`Sheet 4 of 7
`
`US 6,339,142 Bl
`
`-T
`
`I
`
`1
`
`[- ~\
`
`i
`
`r
`
`"i
`
`i
`
`r
`
`"i
`
`r
`
`i
`
`i
`
`r
`
`CO
`cc
`LU
`X
`(-
`O
`
`«/
`
`-i'/^,
`^
`
`S z
`^^mmmmmmm^m^^^^^^s^^mm
`5
`K
`'/////////////////////Z2
`
`CO
`
`I
`CD
`
`<
`LU
`Q.
`X
`CO
`O
`
`wm s
`g
`
`CD
`
`E E E E E
`
`CD D)
`C7) D) O)
`E E E £ E
`un o m o LO
`i- CM CNJ 00 CO
`^ H - 5
`
`E
`en
`E
`o
`
`Si2
`
`Q
`< U
`•
`
`o
`o
`
`"i
`
`1
`
`r
`
`1
`
`r
`
`1
`
`i
`
`r
`
`T
`
`1 r
`
`"i
`
`1
`
`r
`
`o
`CO
`
`o
`CD
`
`o
`
`o
`CNJ
`
`o5-
`
`

`

`Case 1:18-cv-01363-CFC Document 1-9 Filed 09/04/18 Page 7 of 23 PageID #: 416
`
`U.S. Patent
`
`Jan. 15,2002
`
`Sheet 5 of 7
`
`US 6,339,142 Bl
`
`i
`
`i
`
`i I i i i i | i i i i | i i i i | i
`
`i i i
`
`| i i i i
`
`EE E EE E
`
`D) CD CO O) CD 05
`E E E E E E
`in o in o m o
`T- CM CM CO CO rt
`
`WWW
`
`\
`
`\
`
`o o
`
`CO
`
`o
`CM
`
`+
`
`\
`
`\
`
`—
`
`O
`O
`CM
`
`D.
`- • a . ..
`
`• x—
`
`^ —&
`
`.=£L
`
`I
`
`I
`
`I
`
`I
`
`| 1 1
`
`I
`
`I
`
`|
`
`I
`
`I
`
`I
`
`I
`
`|
`
`I
`
`I
`
`I
`
`I
`
`|
`
`I
`
`I
`
`I
`
`I
`
`o
`CO
`
`in
`CM
`
`o
`CM
`
`in
`
`O
`
`in
`o
`
`o
`o
`
`LLl
`O
`<%
`en ^
`ceo
`^ CM
`
`CD
`<
`
`

`

`Case 1:18-cv-01363-CFC Document 1-9 Filed 09/04/18 Page 8 of 23 PageID #: 417
`
`U.S. Patent
`
`Jan. 15,2002
`Jan. 15, 2002
`
`Sheet 6 of 7
`Sheet 6 of 7
`
`US 6,339,142 Bl
`
`in
`
`o
`en
`
`in
`
`o
`
`E-
`
`o
`o
`u
`
`>*
`
`<
`
`Q
`w
`
`u
`>
`>
`CO
`<
`E-
`O
`
`CO
`
`Q
`co
`
`a-
`
`M
`
`>
`CO
`a,
`<
`<
`>
`
`w
`>
`^
`^
`o
`o
`o
`fe
`£-
`a,
`CU
`^
`E-i
`
`3
`i
`CD
`G:
`
`E-
`co
`
`CO
`
`J
`
`CO
`
`CO
`
`Q
`
`CO
`a
`a
`
`>
`CO
`w
`o
`CO
`
`CO
`ex
`
`<
`2
`Q
`>
`
`£
`a
`>
`*;
`<
`w
`ex;
`a,
`
`>H
`
`fc
`2
`2
`J
`
`in
`i£)
`
`O
`in
`
`U5
`
`r -(
`
`O
`
`a
`
`O
`<-(
`
`CO
`
`E-
`>
`
`CO
`
`CO
`
`J
`
`a
`
`>
`w
`a
`<
`
`>H
`
`>
`«
`re
`x
`CJ
`
`>H
`
`Q
`<
`^
`CO
`
`in
`
`tH
`CD
`rH
`
`a<
`<
`
`O
`a.
`
`a
`o
`
`<
`>
`<
`
`z
`>
`Q
`
`O
`
`CO
`
`<
`ex:
`o
`
`M
`
`>
`
`o
`
`-z.
`<
`X
`o
`1-
`X
`CD
`_J
`
`co
`CO
`
`M
`
`in
`r-
`
`o
`(N
`
`in
`o
`
`Q
`
`EH
`
`o
`CO
`
`OS
`
`CO
`U
`CO
`
`fc.
`a;
`CO
`
`>
`O
`CO
`>-
`J
`fc,
`
`CO
`<
`CO
`>•
`M
`
`D
`O m
`
`o
`U3
`
`CO
`<
`M
`
`J
`
`W
`
`Ol
`a.
`CO
`a
`^
`2
`O
`M
`
`1 D
`t—'
`
`1 .J
`
`cn
`
`

`

`Case 1:18-cv-01363-CFC Document 1-9 Filed 09/04/18 Page 9 of 23 PageID #: 418
`
`U.S. Patent
`
`Jan. 15,2002
`
`Sheet 7 of 7
`
`US 6,339,142 Bl
`
`m
`•«q<j
`
`o
`
`i
`a >Q
`
`O
`
`w
`
`n
`n to
`r
`
`o
`S
`w
`
`i
`o ow
`T
`
`r
`< N«
`t
`
`t
`N
`Q
`
`H
`en
`
`om
`r~c/)
`C
`
`sn
`>
`
`I HQ
`
`o
`v o td
`n
`
`O
`
`in
`oo
`^
`
`W
`
`o^
`
`Q ^O
`
`>
`
`3
`
`0
`
`'
`
`M
`
`E
`
`-
`
`'
`
`«
`
`>W
`
`>
`
`<
`
`£
`
`-
`
`<«
`
`:
`
`>
`
`-
`
`i
`
`O
`
`>
`
`Q
`
`C
`
`U>
`
`&
`
`m
`
`£"
`
`>"
`
`wz
`
`K
`
`>H
`
`e-
`
`tr>
`
`w
`
`u:
`
`K
`
`Q
`
`o
`n ^;
`
`^
`
`;
`
`<
`
`J
`
`m
`
`o
`
`r -W
`
`n
`t
`v o r i:
`CNCO
`r H i
`-
`
`o
`
`t
`
`MW
`2
`no
`i
`mS
`rHW
`c N C Nm
`
`o 2 ||
`
`in
`^O
`
`e u w rc
`o
`in
`cnO.
`mJ
`m
`
`'^
`
`n
`
`o
`
`c
`
`o
`
`>
`
`2
`
`2
`
`:
`
`^
`
`cd
`
`u i
`
`c o a CQ
`
`"T
`
`>
`
`c
`
`j
`
`p
`
`c
`
`;
`
`o
`
`i
`
`> H a
`
`. E -'
`
`!
`
`i
`
`i
`
`: >w
`
`•
`
`O
`
`cu
`
`Oi
`
`a
`
`c
`
`n
`
`P
`
`S
`
`>
`
`-
`
`'
`
`O
`
`W>
`
`O
`
`m
`^ (O
`
`o
`
`<
`i
`v o^
`
`o
`
`<
`
`n
`o > -i
`r
`H
`
`P
`
`i
`i n UJ
`r
`-
`
`O
`
`E
`
`-
`
`t
`
`O
`
`o
`
`J
`
`n
`a>co
`r
`H
`
`^W
`in
`' S 'O
`N
`
`C
`
`« >>
`
`CN
`
`J
`
`W
`
`JP
`
`l
`
`i
`
`^
`o
`n <
`r
`
`>
`
`i
`
`O
`
`2
`
`o
`
`U
`
`u
`
`>
`
`c
`
`o
`
`>
`
`-•
`
`H
`
`OI
`no
`r - Cn
`r
`O
`
`"*
`
`C NS
`
`t
`
`dW
`
`jp
`
`>
`^
`
`><P
`n
`
`U
`c
`
`C
`^
`
`J>
`u
`
`M
`[
`>
`J
`0
`
`>
`
`i
`
`C
`
`O
`
`E
`
`-
`
`i
`
`M
`
`i
`
`p
`r
`
`]
`
`i
`c
`
`>
`
`H
`>
`C
`>
`
`U
`-
`^
`
`O
`<
`C
`
`t
`
`'
`
`C
`T
`O
`J
`D
`C
`O W U
`><^P
`
`L
`&
`C
`
`U^
`.>
`iW
`Li
`
`>^
`>
`
`>4
`
`b
`
`^
`
`O
`fc
`
`2
`
`«
`
`CO
`]
`
`>W
`O^
`
`2
`
`M
`
`J
`
`^ HW
`
`V
`O
`ta'Cd
`
`I
`
`H
`cnE-i
`
`V
`
`T
`
`O
`m «
`TH
`
`V
`
`H
`o oO
`TH
`
`D
`TH
`CNE-<
`OI
`
`r - rc
`OJ
`
`D
`
`V
`r nS
`m
`
`H1^
`f
`v oS
`n
`
`ow
`«*
`
`

`

`Case 1:18-cv-01363-CFC Document 1-9 Filed 09/04/18 Page 10 of 23 PageID #: 419
`
`US 6,339,142 Bl
`
`PROTEIN PURIFICATION
`
`This is a divisional of co-pending application No.
`09/304,465 filed May 3, 1999 which claims priority under
`35 USC §119 to provisional application No. 60/084,459 filed 5
`May 6, 1998, both disclosures of which are hereby incor(cid:173)
`porated by reference.
`
`BACKGROUND OF THE INVENTION
`
`1°
`
`30
`
`1. Field of the Invention
`This invention relates generally to protein purification. In
`particular, the invention relates to a method for purifying a
`polypeptide (e.g. an antibody) from a composition compris(cid:173)
`ing the polypeptide and at least one contaminant using the
`method of ion exchange chromatography.
`2. Description of Related Art
`is
`The large-scale, economic purification of proteins
`increasingly an important problem for the biotechnology
`industry. Generally, proteins are produced by cell culture, -.
`using either mammalian or bacterial cell lines engineered to
`produce the protein of interest by insertion of a recombinant
`plasmid containing the gene for that protein. Since the cell
`lines used are living organisms, they must be fed with a
`complex growth medium, containing sugars, amino acids, -,
`and growth factors, usually supplied from preparations of
`animal serum. Separation of the desired protein from the
`mixture of compounds fed
`to the cells and from
`the
`by-products of the cells themselves to a purity sufheient for
`use as a human therapeutic poses a formidable challenge.
`Procedures for purification of proteins from cell debris
`initially depend on the site of expression of the protein.
`Some proteins can be caused to be secreted directly from the
`cell into the surrounding growth media; others are made
`intracellularly. For the latter proteins, the first step of a 35
`purification process involves lysis of the cell, which can be
`done by a variety of methods, including mechanical shear,
`osmotic shock, or enzymatic treatments. Such disruption
`releases the entire contents of the cell into the homogenate,
`and in addition produces subcellular fragments
`that are 40
`difEcult to remove due to their small size. These are gener(cid:173)
`ally removed by differential centrifugation or by
`filtration.
`The same problem arises, although on a smaller scale, with
`directly secreted proteins due to the natural death of cells
`and release of intracellular host cell proteins in the course of 45
`the protein production run.
`Once a clarified solution containing the protein of interest
`has been obtained, its separation from the other proteins
`produced by the cell is usually attempted using a combina(cid:173)
`tion of different chromatography techniques. These tech- 50
`niques separate mixtures of proteins on the basis of their
`charge, degree of hydrophobicity, or size. Several different
`chromatography resins are available for each of
`these
`techniques, allowing accurate tailoring of the purification
`scheme to the particular protein involved. The essence of 55
`each of these separation methods is that proteins can be
`caused either to move at different rates down a long column,
`achieving a physical separation that increases as they pass
`further down the column, or to adhere selectively to the
`separation medium, being then differentially eluted by dif- so
`ferent solvents. In some cases, the desired protein is sepa(cid:173)
`rated from
`impurities when
`the impurities specifically
`adhere to the column, and the protein of interest does not,
`that is, the protein of interest is present in the "flow-
`through".
`
`Ion exchange chromatography is a chromatographic tech(cid:173)
`nique that is commonly used for the purification of proteins.
`
`65
`
`In ion exchange chromatography, charged patches on the
`surface of the solute are attracted by opposite charges
`attached to a chromatography matrix, provided the ionic
`strength of the surrounding buffer is low. Elution is generally
`achieved by increasing the ionic strength (i.e. conductivity)
`of the buffer to compete with the solute for the charged sites
`of the ion exchange matrix. Changing the pH and thereby
`altering the charge of the solute is another way to achieve
`elution of the solute. The change in conductivity or pH may
`be gradual (gradient elution) or stepwise (step elution). In
`the past, these changes have been progressive; i.e., the pH or
`conductivity is increased or decreased in a single direction.
`
`SUMMARY OF THE INVENTION
`The present invention provides an ion exchange chro(cid:173)
`matographic method wherein a polypeptide of interest is
`bound to the ion exchange material at an initial conductivity
`or pH and then the ion exchange material is washed with an
`intermediate buffer at a different conductivity or pH, or both.
`At a specific point following this intermediate wash, and
`contrary to ion exchange chromatography standard practice,
`the ion exchange material is washed with a wash buffer
`where the change in conductivity or pH, or both, from the
`intermediate buffer to the wash buffer is in an opposite
`direction to the change in conductivity or pH, or both,
`achieved in the previous steps. Only after washing with the
`wash buffer, is the ion exchange material prepared for the
`polypeptide molecule of interest to be eluted by the appli(cid:173)
`cation of the elution buffer having a conductivity or pH, or
`both, which differ from the conductivity or pH, or both, of
`the buffers used in previous steps.
`
`This novel approach to ion exchange chromatography is
`particularly useful in situations where a product molecule
`must be separated from a very closely related contaminant
`molecule at full manufacturing scale, where both purity and
`high recovery of polypeptide product are desired.
`Accordingly, the invention provides a method for purify(cid:173)
`ing a polypeptide from a composition comprising
`the
`polypeptide and a contaminant, which method comprises the
`following steps performed sequentially:
`(a) binding the polypeptide to an ion exchange material
`using a loading buffer, wherein the loading buffer is at
`a first conductivity and pH;
`(b) washing the ion exchange material with an interme(cid:173)
`diate buffer at a second conductivity and/or pH so as to
`elute the contaminant from the ion exchange material;
`(c) washing the ion exchange material with a wash buffer
`which is at a third conductivity and/or pH, wherein the
`change in conductivity and/or pH from the intermediate
`buffer to the wash buffer is in an opposite direction to
`the change in conductivity and/or pH from the loading
`buffer to the intermediate buffer; and
`(d) washing the ion exchange material with an elution
`buffer at a fourth conductivity and/or pH so as to elute
`the polypeptide from the ion exchange material. The
`first conductivity and/or pH may be the same as the
`third conductivity and/or pH.
`Where the ion exchange material comprises a cation
`exchange resin, the conductivity and/or pH of the interme(cid:173)
`diate buffer is/are preferably greater than the conductivity
`and/or pH of the loading buffer; the conductivity- and/or pH
`of the wash buffer is/are preferably less than the conductivity
`and/or pH of the intermediate buffer; and the conductivity
`and/or pH of the elution buffer is/are preferably greater than
`the conductivity and/or pH of the intermediate buffer.
`Preferably, the conductivity and/or pH of the wash buffer
`is/are about the same as the conductivity and/or pH of the
`loading buffer.
`
`

`

`Case 1:18-cv-01363-CFC Document 1-9 Filed 09/04/18 Page 11 of 23 PageID #: 420
`
`US 6,339,142 Bl
`
`Preferably elution of the contaminant and of the polypep(cid:173)
`tide is achieved by modifying the conductivity of the inter(cid:173)
`mediate buffer and of the elution buffer, respectively, while
`keeping the pH of these buffers approximately the same.
`The invention also provides a method for purifying a 5
`polypeptide from a composition comprising the polypeptide
`and a contaminant, which method comprises the following
`steps performed sequentially:
`(a) binding the polypeptide to a cation exchange material
`using a loading buffer, wherein the loading buffer is at 1°
`a first conductivity and pH;
`(b) washing the cation exchange material with an inter(cid:173)
`mediate buffer at a second conductivity and/or pH
`which is greater than that of the loading buffer so as to
`elute the contaminant from the ion exchange material; 15
`(c) washing the cation exchange material with a wash
`buffer which is at a third conductivity and/or pH which
`is less than that of the intermediate buffer; and
`(d) washing the cation exchange material with an elution
`buffer at a fourth conductivity and/or pH which is
`greater than that of the intermediate buffer so as to elute
`the polypeptide from the ion exchange material.
`In addition, the invention provides a method for purifying
`an antibody from a composition comprising the antibody
`and a contaminant, which method comprises loading the
`composition onto a cation exchange resin, wherein the
`amount of antibody loaded onto the cation exchange resin is
`from about 20 mg to about 35 mg of the antibody per mL of
`cation exchange resin and, optionally, further comprising
`eluting the antibody from the cation exchange resin. The
`method preferably further comprises an intermediate wash
`step for eluting one or more contaminants from the ion
`exchange resin. This intermediate wash step usually pre(cid:173)
`cedes the step of eluting the antibody.
`The invention further provides a composition comprising
`a mixture of anti-HER2 antibody and one or more acidic
`variants thereof, wherein the amount of the acidic variant(s)
`in the composition is less than about 25% and preferably less
`than about 20%, e.g. in the range from about 1% to about
`18%. Optionally, the composition further comprises a phar-
`maceutically acceptable carrier
`
`,
`
`45
`
`BRIEF DESCRIPTION OF THE DRAWINGS
`FIG. 1 is a flow diagram showing how one could perform
`cation exchange chromatography by altering conductivity
`(e.g. to the NaCl concentrations of Example 1 below) or by
`altering pH (e.g. to the pH values as shown in the flow
`diagram).
`FIG. 2 is a flow diagram showing how one could perform 50
`anion exchange chromatography by altering conductivity
`(e.g. to the Nacl concentrations as depicted in the figure) or
`by altering pH (e.g. to the pH values as shown).
`FIG. 3 is an absorbance trace from a cation exchange
`chromatography run of Example 1 at full manufacturing 55
`scale. Points at which the column is washed with the
`different buffers described herein are marked with arrows.
`FIG. 4 depicts recombinant humanized anti-HER2 mono(cid:173)
`clonal antibody (rhuMAb HER2) recovered in each chro(cid:173)
`matography fraction (calculated as the percentage of the sum 60
`total of all fractions of the relevant chromatography). Flow
`through, wash steps, and prepool fractions are all effluent
`samples collected from the onset of load to the initiation of
`pooling. The pool fraction is the five column volume effluent
`sample of elution starting at the leading shoulder's inflection 65
`point. The regeneration fraction contains effluent captured
`from the end of pooling to the end of regeneration.
`
`FIG. 5 shows the quality of rhuMAb HER2 in each cation
`exchange chromatography pool sample as evaluated by
`carboxy sulfon cation exchange high pressure liquid chro(cid:173)
`matography (CSx HPIEX). Peaks a, b, and 1 are deamidated
`forms of rhuMAb HER2. Peak 3 is nondeamidated rhuMAb
`HER2. Peak 4 is a combination of C-terminal Lysine con(cid:173)
`taining and iso-aspartate variants of rhuMAb HER2.
`FIG. 6 shows the absorbance (280 nm) profiles of the
`0.025 M MES/0.070 M NaCl, pH 5.6 wash for each chro(cid:173)
`matography. The mass of rhuMAb HER2 applied to the
`cation exchange resin effects the peak's absorbance level at
`the apex as well as the amount of buffer required to reach the
`apex. Due to minor peaks which occur (as best seen in the
`30 mg/mL load) in this wash, the apex is defined as
`absorbance levels of at least 0.5 absorbance units (AU).
`FIGS. 7A and 7B show the amino acid sequences of
`humMAb4D5-8
`light chain (SEQ ID NO:l) and
`humMAb4D5-8 heavy chain (SEQ ID NO:2), respectively.
`
`DETAILED DESCRIPTION OF THE
`PREFERRED EMBODIMENTS
`
`Definitions:
`The "composition" to be purified herein comprises the
`polypeptide of interest and one or more contaminants. The
`composition may be "partially purified" (i.e. having been
`subjected to one or more purification steps, such as Protein
`A Chromatography as in Example 1 below) or may be
`obtained directly from a host cell or organism producing the
`polypeptide (e.g. the composition may comprise harvested
`cell culture fluid).
`As used herein, "polypeptide" refers generally to peptides
`and proteins having more than about ten amino acids.
`Preferably, the polypeptide is a mammalian protein,
`examples of which include renin; a growth hormone, includ(cid:173)
`ing human growth hormone and bovine growth hormone;
`growth hormone releasing factor; parathyroid hormone;
`thyroid stimulating hormone; lipoproteins; alpha-1-
`antitrypsin; insulin A-chain; insulin B-chain; proinsulin;
`follicle stimulating hormone; calcitonin; luteinizing hor(cid:173)
`mone; glucagon; clotting factors such as factor VIIIC, factor
`IX, tissue factor, and von Willebrands factor; anti-clotting
`factors such as Protein C; atrial natriuretic factor; lung
`surfactant; a plasminogen activator, such as urokinase or
`human urine or tissue-type plasminogen activator (t-PA);
`bombesin; thrombin; hemopoietic growth factor; tumor
`necrosis factor-alpha and -beta; enkephalinase; RANTES
`(regulated on activation normally T-cell expressed and
`secreted); human macrophage inflammatory protein (MIP-
`1-alpha); a serum albumin such as human serum albumin;
`Muellerian-inhibiting substance; relaxin A-chain; relaxin
`B-chain; prorelaxin; mouse gonadotropin-associated pep(cid:173)
`tide; a microbial protein, such as beta-lactamase; DNase;
`IgE; a cytotoxic T-lymphocyte associated antigen (CTLA),
`such as CTLA-4; inhibin; activin; vascular endothelial
`growth factor (VEGF); receptors for hormones or growth
`factors; Protein A or D; rheumatoid factors; a neurotrophic
`factor such as bone-derived neurotrophic factor (BDNF),
`neurotrophin-3, -4, -5, or -6 (NT-3, NT-4, NT-5, or NT-6), or
`a nerve growth factor such as NGF-P; platelet-derived
`growth factor (PDGF); fibroblast growth factor such as
`aFGF and bFGF; epidermal growth factor (EGF); transform(cid:173)
`ing growth factor (TGF) such as TGF-alpha and TGF-beta
`including TGF-pi, TGF-P2, TGF-P3, TGF-P4, or TGF-P5
`insulin-like growth factor-I and -II (IGF-I and IGF-II)
`des(l-3)-IGF-I (brain IGF-I), insulin-like growth factor
`binding proteins (IGFBPs); CD proteins such as CD3, CD4,
`CDS, CD19 and CD20; erythropoietin; osteoinductive fac-
`
`

`

`Case 1:18-cv-01363-CFC Document 1-9 Filed 09/04/18 Page 12 of 23 PageID #: 421
`
`US 6,339,142 Bl
`
`tors; immunotoxins; a bone morphogenetic protein (BMP);
`an interferon such as interferon-alpha, -beta, and -gamma;
`colony stimulating factors (CSFs), e.g., M-CSF, GM-CSF,
`and G-CSF; interleukins (ILs), e.g., IL-1 to IL-10; superox(cid:173)
`ide dismutase; T-cell receptors; surface membrane proteins; 5
`decay accelerating factor; viral antigen such as, for example,
`a portion of the AIDS envelope; transport proteins; homing
`receptors; addressins; regulatory proteins; integrins such as
`C D l l a, C D l l b, C D l l c, CD18, an ICAM, VLA-4 and
`VCAM; a tumor associated antigen such as HER2, HER3 or 10
`HER4 receptor; and fragments and/or variants of any of the
`above-listed polypeptides. Most preferred is a full length
`antibody that binds human HER2.
`A "contaminant" is a material that is different from the
`desired polypeptide product. The contaminant may be a 15
`variant of the desired polypeptide (e.g. a deamidated variant
`or an amino-aspartate variant of the desired polypeptide) or
`another polypeptide, nucleic acid, endotoxin etc.
`A "variant" or "amino acid sequence variant" of a starting
`polypeptide is a polypeptide that comprises an amino acid 20
`sequence different from that of the starting polypeptide.
`Generally, a variant will possess at least 80% sequence
`identity, preferably at least 90% sequence identity, more
`preferably at least 95% sequence identity, and most prefer(cid:173)
`ably at least 98% sequence identity with the native polypep- 25
`tide. Percentage sequence
`identity
`is determined,
`for
`example, by the Fitch et al., Proc. Natl. Acad. Sci. USA
`80:1382-1386 (1983), version of the algorithm described by
`Needleman et a l, /. Mol. Biol. 48:443-453 (1970), after
`aligning the sequences to provide for maximum homology. 30
`Amino acid sequence variants of a polypeptide may be
`prepared by introducing appropriate nucleotide changes into
`DNA encoding the polypeptide, or by peptide synthesis.
`Such variants include, for example, deletions from, and/or
`insertions into and/or substitutions of, residues within the 35
`amino acid sequence of the polypeptide of interest. Any
`combination of deletion, insertion, and substitution is made
`to arrive at the final construct, provided
`that the final
`construct possesses the desired characteristics. The amino
`acid changes also may alter post-translational processes of 40
`the polypeptide, such as changing the number or position of
`glycosylation sites. Methods for generating amino acid
`sequence variants of polypeptides are described in U.S. Pat.
`No. 5,534,615, expressly incorporated herein by reference,
`for example.
`
`45
`
`An "acidic variant" is a variant of a polypeptide of interest
`which is more acidic (e.g. as determined by cation exchange
`chromatography)
`than
`the polypeptide of
`interest. An
`example of an acidic variant is a deamidated variant.
`A "deamidated" variant of a polypeptide molecule is a 50
`polypeptide wherein one or more asparagine residue(s) of
`the original polypeptide have been converted to aspartate,
`i.e. the neutral amide side chain has been converted to a
`residue with an overall acidic character. Deamidated
`humMAb4D5 antibody from the Example below has Asn30 55
`in CDR1 of either or both of the V^ regions
`thereof
`converted
`to aspartate. The
`term "deamidated human
`DNase" as used herein means human DNase that is deami(cid:173)
`dated at the asparagine residue that occurs at position 74 in
`the amino acid sequence of native mature human DNase 60
`(U.S. Pat. No. 5,279,823; expressly incorporated herein by
`reference).
`The term "mixture" as used herein in reference to a
`composition comprising an anti-HER2 antibody, means the
`presence of both the desired anti-HER2 antibody and one or 65
`more acidic variants thereof. The acidic variants may com(cid:173)
`prise predominantly deamidated anti-HER2 antibody, with
`
`minor amounts of other acidic variant(s). It has been found,
`for example, that in preparations of anti-HER2 antibody
`obtained from recombinant expression, as much as about
`25% of the anti-HER2 antibody is deamidated.
`In preferred embodiments of the invention, the polypep(cid:173)
`tide is a recombinant polypeptide. A "recombinant polypep(cid:173)
`tide" is one which has been produced in a host cell which has
`been transformed or transfected with nucleic acid encoding
`the polypeptide, or produces the polypeptide as a result of
`homologous recombination.
`inter(cid:173)
`"Transformation" and "transfection" are used
`changeably to refer to the process of introducing nucleic
`acid into a cell. Following transformation or transfection, the
`nucleic acid may integrate into the host cell genome, or may
`exist as an extrachromosomal element. The "host cell"
`includes a cell in in vitro cell culture as well a cell within a
`host animal. Methods for recombinant production of
`polypeptides are described in U.S. Pat. No. 15 5,534,615,
`expressly incorporated herein by reference, for example.
`The term "antibody" is used in the broadest sense and
`specifically covers monoclonal antibodies (including full
`length monoclonal antibodies), polyclonal antibodies, mul-
`tispecific antibodies (e.g., bispecific antibodies), and anti(cid:173)
`body fragments so long as they exhibit the desired biological
`activity.
`The antibody herein is directed against an "antigen" of
`interest. Preferably, the antigen is a biologically important
`polypeptide and administration of the antibody to a mammal
`suffering from a disease or disorder can result in a thera(cid:173)
`peutic benefit in that mammal. However, antibodies directed
`against nonpolypeptide antigens (such as tumor-associated
`glycolipid antigens; see U.S. Pat. No. 5,091,178) are also
`contemplated. Where the antigen is a polypeptide, it may be
`a transmembrane molecule (e.g. receptor) or ligand such as
`a growth factor. Exemplary antigens include those polypep(cid:173)
`tides discussed above. Preferred molecular targets for anti(cid:173)
`bodies encompassed by the present invention include CD
`polypeptides such as CD3, CD4, CDS, CD19, CD20 and
`CD34; members of the HER receptor family such as the
`EGF receptor, HER2, HER3 or HER4 receptor; cell adhe(cid:173)
`sion molecules such as LFA-1, Macl, pl50,95, VLA-4,
`ICAM-1, VCAM and av/b3 integrin including either a or b
`subunits thereof (e.g. anti-CDlla, anti-CD18 or anti-CDllb
`antibodies); growth factors such as VEGF; IgE; blood group
`antigens; flk2/flt3 receptor; obesity (OB) receptor; mpl
`receptor; CTLA-4; polypeptide C etc. Soluble antigens or
`fragments thereof, optionally conjugated to other molecules,
`can be used as immunogens for generating antibodies. For
`transmembrane molecules, such as receptors, fragments of
`these (e.g. the extracellular domain of a receptor) can be
`used as the immunogen. Alternatively, cells expressing the
`transmembrane molecule can be used as the immunogen.
`Such cells can be derived from a natural source (e.g. cancer
`cell lines) or may be cells which have been transformed by
`recombinant techniques to express the transmembrane mol(cid:173)
`ecule.
`
`The term "monoclonal antibody" as used herein refers to
`an antibody obtained from a population of substantially
`homogeneous antibodies, i.e., the individual antibodies
`comprising the population are identical except for possible
`naturally occurring mutations that may be present in minor
`amounts. Monoclonal antibodies are highly specific, being
`directed against a single antigenic site. Furthermore, in
`contrast to conventional (polyclonal) antibody preparations
`which typically include different antibodies directed against
`different determinants (epitopes), each monoclonal antibody
`is directed against a single determinant on the antigen. The
`
`

`

`Case 1:18-cv-01363-CFC Document 1-9 Filed 09/04/18 Page 13 of 23 PageID #: 422
`
`US 6,339,142 Bl
`
`modifier "monoclonal" indicates the character of the anti(cid:173)
`body as being obtained from a substantially homogeneous
`population of antibodies, and is not to be construed as
`requiring production of the antibody by any particular
`method. For example, the monoclonal antibodies to be used 5
`in accordance with the present invention may be made by the
`hybridoma method first described by Kohler et al., Nature
`256:495 (1975), or may be made by recombinant DNA
`methods (see, e.g., U.S. Pat. No. 4,816,567). In a fur